At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
LY2090314drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2090314 in Participants With Acute Leukemia
In Brief
A Phase 2 clinical trial evaluating LY2090314 for Leukemia. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
This study is a multicenter, non-randomized, open-label, Phase 2 study of intravenous LY2090314 in participants with acute leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionDec 2012
TodayJul 2026
First PostedOct 5, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.7 years ago
Interventions
LY2090314drug
Administered intravenously